Remove 2030 Remove Competition Remove Leads
article thumbnail

Sorry, the Inflation Bill won’t lower healthcare costs

World of DTC Marketing

1ne: A new analysis predicts that by 2030, 48.9% This is going to lead to a lot of health problems and associated costs. Increased provider consolidation has decreased individual market competition, in which lower prices, improved productivity, and innovation can occur. of adults in the United States will be obese, and 24.2%

article thumbnail

4D Molecular’s Fabry gene therapy program on FDA clinical hold

Pharmaceutical Technology

4DMT is creating a gene therapy using an adeno-associated viral vector (AAV) and there is currently competition from several early-stage therapies in trial, such as Sangamo Therapeutics’s Fabry gene therapy that is currently at Phase III, which also uses AAV, and as of November 2022 has reported it is progressing to late-stage plans.

FDA 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Eli Lilly achieving significant gains in obesity results

Pharmaceutical Technology

Eli Lilly has achieved significant gains in the past quarter, leading to it becoming the most valuable pharmaceutical company in the world, with a market cap of $420bn, surpassing Johnson & Johnson. There have been several Phase III trials for Mounjaro, with SURMOUNT-1 demonstrating a weight loss of up to 22.5%

Leads 98
article thumbnail

2022 Sales Hiring Forecast

Sales Talent

However, before you jump directly to our sales hiring predictions for 2022, take the time to read the entire article to learn how the intense competition for talent is impacting sales professionals’ salaries and employers’ strategies for winning the talent war. jobs by 2030 while the workforce will only grow by 8.9M.

Sales 130
article thumbnail

Sun Pharma agrees deal to buy alopecia player Concert

pharmaphorum

India’s Sun Pharmaceutical has signed an agreement to acquire US biotech Concert Pharmaceuticals and its lead drug deuroxilitinib, in phase 3 testing for alopecia areata, a leading cause of hair loss. The $11.50 The report predicts that the alopecia areata market will grow to as much as $2.5

Pharma 98
article thumbnail

Enhancing Patient Engagement Through Gamification in Healthcare

LEVO Health

Between 2023 and 2030, that number is expected to grow at a compound annual growth rate of 22.6%. This may lead to better treatment outcomes, increased adherence to medication plans, and improved patient satisfaction. This approach has improved adherence rates, leading to better health outcomes. billion dollars.

article thumbnail

Horizon Europe deal signals UK research reinvigoration

European Pharmaceutical Review

It will also lead to greater regulatory alignment between the UK and EU, providing a huge boost to exporters, as well as improving the talent pool available to businesses and allowing for easier movement of researchers and professionals between the UK and the EU,” Brain explained.